Risk-based monitoring could be a boon to CROs

Now that the FDA is encouraging drugmakers to consider risk-based monitoring for clinical trials, CROs that have already invested in adaptive trials could stand to benefit. As North Carolina's News & Observer points out, getting into the risk-based business would require up-front investment by drug developers, but the likes of Quintiles ($Q), INC Research and PRA are already well-versed in the method, positioning them to cash in on the trend. Report